Pharma News

Western Ghats Task Force Board increases more Medicinal Plants Conservation Areas in Karnataka

Western Ghats Task Force Board has now designated Medicinal Plants Conservation Areas (MPCAs) in more number of locations in the State. The plan of action is to have one MPCA in every district. The matter is being taken ahead in consultation with the Bangalore-based Foundation for Revitalization of Local Health Traditions (FRLHT). A meeting of scientists and officials of the state forest department would be held to discuss the plan of action, said Ananth Hedge Ashisara, chairperson Western Ghats Task Force.

NIPER to induct more scientists to help SME industry through SMPIC

The NIPER, Mohali will appoint a few more scientists and faculty on ad-hoc basis in the next three-six months to extend all required services to the small and medium sector pharma companies under the aegis of the Small and Medium Pharmaceutical Industry Centre (SMPIC) and make it fully useful for the struggling industry.

Worlds poor to get pneumonia vaccines at affordable cost

In a novel agreement, two global pharma majors have planned to make available their top-selling pneumonia vaccines at one-eighth of the market rates to save lives of poor children in developing countries.

Every day, 4,384 people, mostly children below the age of five, die due to preventable pneumococcal diseases, primarily pneumonia and meningitis. Most of these deaths, 1.6 million in a year, occur in some of the world’s poorest countries.

CPhI China to be held in Shanghai from June 2 to 4

Shanghai will be playing host to UBM International Media events CPhI, P-MEC, ICSE and BioPh From June 2 to 4. While CPhI will be focusing on intermediates and APIs markets, ICSE is for contract services and P-MEC exhibitors offer a complete range of pharma machinery and equipment. BioPh is aimed at those who provide bio-solutions for pharma.

Last year’s events attracted more than 23,000 attendees from 102 countries and more than 1,600 exhibitors, 127 of which were international companies.

LCT gets approval to advance to phase-II human trial with Diabecell

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received approval to advance to the next phase of its New Zealand phase-II human clinical trial with its groundbreaking Diabecell. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its Diabecell implants.

Allergan, Serenity Pharma enter global pact for the treatment of nocturia

Allergan, Inc. and Serenity Pharmaceuticals, LLC announced a global agreement for the development and commercialization of Ser-120, a phase III investigational drug currently in clinical development for the treatment of nocturia, a common yet often under-diagnosed urological disorder in adults characterized by frequent urination at night time.

Pages